Association of Corynebacterium pseudotuberculosis recombinant proteins rCP09720 or rCP01850 with rPLD as immunogens in caseous lymphadenitis immunoprophylaxis

Assessment of the acid phosphatase CP01850 from Corynebacterium pseudotuberculosis in DNA and subunit vaccine formulations against caseous lymphadenitis

“…We hypothesized that the use of only rCP01850 is possibly insufficient to provide adequate levels of protection, requiring an evaluation of which important recombinant proteins related to C. pseudotuberculosis pathogenesis should be associated to improve protection. In fact, in recent publication, our group has demonstrated that when rCP01850 protein was associated to rPLD in a saponin-adjuvanted vaccine, protection rate was improved by 20% in comparison to the use of rPLD alone, and a significant (P< 0.05) production of IFN-γ in mice was obtained, demonstrating the benefit of including rCP01850 in CLA vaccine formulations (Silva et al, 2018). So, rCP01850 had an additive effect in formulations containing more than one protein, but here, the same protein was insufficient for conferring protection when used alone adjuvanted with aluminum hydroxide.…”

“…The DNA vaccine pTARGET/cp09720 induced a significant increase in IFN-γ levels, indicating a Th1 response, the phenotype related to CLA protection (Brum et al, 2017). Also, recombinant subunit vaccines have been tested for CLA immune prophylaxis, since they are considered safe for inducing lower levels of side effects, resulting in variable protection rates depending on the C. pseudotuberculosis antigen selected (Hodgson et al, 1999;Pinho et al, 2009;Silva et al, 2014;Droppa-Almeida et al 2016;Brum et al 2017;Silva et al, 2018).…”

“…Our group has recently demonstrated that rCP01850 protein associated with rPLD in a saponin-adjuvanted vaccine significantly increases the protection rate and IFN-γ mRNA levels against CLA (Silva et al, 2018). However, the use of the recombinant acid phosphatase CP01850 alone in CLA vaccines was not demonstrated yet.…”

Vaccines for caseous lymphadenitis: up-to-date and forward-looking strategies

“…Studies applying subunit recombinant vaccines against CLA have been in evidence in recent years mainly by their safety, related to the use of pure or semi-pure antigens and by advances in bioinformatics approaches that allowed the identification of proteins or glycoproteins with potential protective effect (Doytchinova and Flower 2007;Rezende et al 2016). To date, several studies have used the subunit recombinant vaccine strategy against caseous lymphadenitis (Pinho et al 2009;Selim et al 2010;Silva et al 2014;Droppa-almeida et al 2016;Brum et al 2017;Silva et al 2018;Leal et al 2018;Rezende et al 2020;Bezerra et al 2020). This strategy uses only a part of the pathogen for immune recognition; however, the high purity level decreases its immunogenicity, requiring adjuvants to improve the immune response (Christensen 2016).…”

“…This strategy uses only a part of the pathogen for immune recognition; however, the high purity level decreases its immunogenicity, requiring adjuvants to improve the immune response (Christensen 2016). Due to this fact, different adjuvants have already been tested in combination to recombinant proteins: Freund's complete adjuvant (Pinho et al 2009;Droppaalmeida et al 2016), mineral oil (Selim et al 2010), saponin (Silva et al 2014;Droppa-almeida et al 2016;Silva et al 2018), aluminum hydroxide (Brum et al 2017;Rezende et al 2020), and more recently, propolis (Bezerra et al 2020).…”